
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a promising trajectory in its clinical trials, with positive data emerging from both its Phase 2a study for colorectal cancer treatment and its Phase 2 study addressing post-COVID conditions using Ampligen. The consistent flow of encouraging results indicates strong potential catalysts for the company's stock as it continues to validate the efficacy of its flagship therapeutics in addressing unmet medical needs. Given this positive data trend, AIM ImmunoTech's focus on innovative immunotherapy solutions positions it favorably within the biotechnology sector, suggesting a robust outlook ahead.
Bears say
AIM ImmunoTech reported a net loss of $3.3 million with an earnings per share (EPS) of $(1.57), significantly exceeding expectations and indicating weaker financial performance than earlier estimates. Additionally, the company faces numerous risks including liquidity challenges, potential failures in clinical trials, and hurdles in obtaining regulatory approvals, all of which could impact its future viability and stock performance. The presence of these risks, coupled with the company's ongoing financial losses, contributes to a negative outlook on AIM ImmunoTech’s stock.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares